Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $42.0 million.

  • Mimedx Group's Net Income towards Common Stockholders rose 112.59% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year decrease of 48.57%. This contributed to the annual value of $42.0 million for FY2024, which is 24.73% down from last year.
  • Mimedx Group's Net Income towards Common Stockholders amounted to $42.0 million in FY2024, which was down 24.73% from $55.8 million recorded in FY2023.
  • Mimedx Group's 5-year Net Income towards Common Stockholders high stood at $55.8 million for FY2023, and its period low was -$83.3 million during FY2020.
  • In the last 3 years, Mimedx Group's Net Income towards Common Stockholders had a median value of $42.0 million in 2024 and averaged $23.8 million.
  • In the last 5 years, Mimedx Group's Net Income towards Common Stockholders slumped by 225.75% in 2020 and then skyrocketed by 310.29% in 2023.
  • Mimedx Group's Net Income towards Common Stockholders (Yearly) stood at -$83.3 million in 2020, then skyrocketed by 77.87% to -$18.4 million in 2021, then plummeted by 43.91% to -$26.5 million in 2022, then surged by 310.29% to $55.8 million in 2023, then dropped by 24.73% to $42.0 million in 2024.